AstraZeneca plc: Is It Still A Buy Now That Pfizer Has Gone?

Should you buy what Pfizer couldn’t? Harvey Jones examines the case for AstraZeneca plc (LON: AZN).

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

AstraZenecaAfter all the excitement surrounding the Pfizer takeover bid, here comes the hangover for investors in AstraZeneca (LSE: AZN) (NYSE: AZN.US). The UK’s second-largest pharmaceutical company’s share price fell 12% after management snubbed Pfizer’s final offer, disappointing traders who bought the stock hoping to make a fast buck.

We’re not traders at the Motley Fool, we’re investors. We like to buy companies at tempting valuations then hold them for the long -term, reinvesting our dividends while we wait for the share price to deliver some capital growth as well. In that respect, we feel more comfortable buying AstraZeneca now that takeover talk is subsiding.

Soriot, So Good

And there are good long-term reasons to buy this stock, not least the performance of chief executive Pascal Soriot. He laid down a marker early in his tenure, by scrapping the company’s share buyback scheme. That was a disappointment for investors, but the right move for the company, as part of his strategy to cut costs, target key markets, replenish the company’s dwindling drugs pipeline and avoid the looming patent cliff.

Soriot has taken arms against a sea of troubles, including government cutbacks in Europe, healthcare reform in the US, sluggish emerging market sales, and a slew of broker downgrades. He must feel vindicated today, with significant figures such as fund management legend Neil Woodford and Vince Cable rushing to proclaim AstraZeneca’s strategic importance to the UK, and top 20 shareholders such as Fidelity and Threadneedle manning the barricades against the US invader.

Jam Sandwich

Now we’ll find out whether they were right. The signs look promising, as Threadneedle said, this “is a strong, standalone UK business with a good product pipeline”, that has made notable progress under Soriot. But shareholders are clearly being told to forego jam today, and a big gooey £55-a-share dollop of it at that, in the hope of jam tomorrow and tomorrow and tomorrow. As with any stock, buying AstraZeneca today is an act of faith.

Setting a value on its pipeline of drugs needs more than faith, it requires almost mystical powers. All we can say is that AstraZeneca boasts 19 products entering late stage trials between now and the end of next year, so even with a moderate strike rate, investors have reason to be hopeful. Yesterday, broker UBS raised its target price from 4825p to 5000p, maintaining its buy recommendation. Today, you pay 4326p, some 16% below that. While you wait, you can bank your dividends, which currently offer a yield of 4.2%.

The Pfizer bid isn’t completely dead. It has until Monday to re-open talks. So traders could still get their rewards, but I remain hopeful that investors will be the real winners in the end.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Harvey doesn't own shares in any company mentioned in this article.

More on Investing Articles

Young female business analyst looking at a graph chart while working from home
Investing Articles

Why I think Rolls-Royce shares will pay a dividend in 2024

Stephen Wright thinks Rolls-Royce shares are about to pay a dividend again. But he isn’t convinced this is something investors…

Read more »

Investing Articles

1 of the best UK shares to consider buying in April

Higher gold prices and a falling share price have put this FTSE 250 stock on Stephen Wright's list of UK…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

The market is wrong about this FTSE 250 stock. I’m buying it in April

Stephen Wright thinks investors should look past a 49% decline in earnings per share and consider investing in a FTSE…

Read more »

Black father and two young daughters dancing at home
Investing Articles

1 FTSE 250 stock I own, and 1 I’d love to buy

Our writer explains why she’s eyeing up this FTSE 250 growth phenomenon, and may buy more shares in this property…

Read more »

View of Tower Bridge in Autumn
Investing Articles

The FTSE 100 is closing in on 8,000 points! Here’s what I’m buying before it’s too late!

As the FTSE 100 keeps gaining momentum, this Fool is on the lookout for bargains. Here's one stock he'd willingly…

Read more »

Investing Articles

3 ideas to help investors aim for a million-pound Stocks & Shares ISA

The UK has a growing number of Stocks and Shares ISA millionaires, and this plan may be one of the…

Read more »

Illustration of flames over a black background
Investing Articles

2 red-hot UK growth stocks to consider buying in April

These two growth stocks are performing well, but can they continue to deliver for investors through 2024 and beyond?

Read more »

Charticle

Is JD Sports Fashion one of the FTSE 100’s best value stocks? Here’s what the charts say!

The JD Sports Fashion share price remains a wild ride during the first quarter. Could it be one of the…

Read more »